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What is the key question? 1 
Are there serum host marker signatures, which are suitable for point-of-care tests that 2 
differentiate between active pulmonary TB and other conditions in individuals presenting with 3 
signs and symptoms suggestive of TB in primary health care settings in Africa? 4 
 5 
What is the bottom line? 6 
A seven-marker host serum protein biosignature consisting of CRP, transthyretin, IFN-γ, complement 7 
factor H, apolipoprotein-A1, IP-10 and serum amyloid A, is promising as a diagnostic biosignature for 8 
TB disease, regardless of HIV infection status or African country of sample origin. 9 
 10 
Why read on?  11 
The 7 serum marker biosignature identified in this large multi-centered study on 716 individuals with 12 
signs and symptoms suggestive of TB could form the basis of a rapid, point-of-care screening test, and 13 
with a sensitivity of 94% and negative predictive value of 96%, such a test would render about 75% of 14 
the currently performed GeneXpert or TB cultures unnecessary.  15 
  16 
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ABSTRACT  69 
Background 70 
User-friendly, rapid, inexpensive yet accurate TB diagnostic tools are urgently needed at 71 
points-of-care in resource-limited settings. We investigated host biomarkers detected in serum 72 
samples obtained from adults with signs and symptoms suggestive of TB at primary health care 73 
clinics in five African countries (Malawi, Namibia, South Africa, The Gambia, and Uganda), 74 
for the diagnosis of TB disease.  75 
 76 
Methods  77 
We prospectively enrolled individuals presenting with symptoms warranting investigation for 78 
pulmonary TB, prior to assessment for TB disease. We evaluated 22 host protein biomarkers 79 
in stored serum samples using a multiplex cytokine platform. Using a pre-established 80 
diagnostic algorithm comprising of laboratory, clinical and radiological findings, participants 81 
were classified as either definite TB, probable TB, questionable TB status or non-pulmonary 82 
TB.  83 
 84 
Results 85 
Of the 716 participants enrolled, 185 were definite and 29 were probable TB cases, six had 86 
questionable TB disease status, whereas 487 had no evidence of TB. A seven-marker 87 
biosignature of CRP, transthyretin, IFN-γ, CFH, apolipoprotein-A1, IP-10 and SAA identified 88 
on a training sample set (n=491), diagnosed TB disease in the test set (n=210) with sensitivity 89 
of 93.8% (95% CI, 84.0-98.0%), specificity of 73.3% (95% CI, 65.2-80.1%), and positive and 90 
negative predictive values of 60.6% (95% CI, 50.3-70.1) and 96.4% (95% CI, 90.5-98.8%) 91 
respectively, regardless of HIV infection status or study site.  92 
 93 
Conclusion: 94 
We have identified a seven-marker host serum protein biosignature for the diagnosis of TB 95 
disease irrespective of HIV infection status or ethnicity in Africa. These results hold promise 96 
for the development of a field-friendly point-of-care screening test for pulmonary TB. 97 
 98 
 99 
  100 
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INTRODUCTION: 101 
Tuberculosis (TB) remains a global health problem with an estimated 9.6 million people 102 
reported to have fallen ill with the disease and 1.5 million deaths in 20141. Sputum smear 103 
microscopy, which has well described limitations, particularly sensitivity2, remains the  most 104 
commonly used diagnostic test for TB in resource-constrained settings. Mycobacterium 105 
tuberculosis (M.tb) culture, the reference standard test, has a long turn-around time2, is 106 
expensive, prone to contamination and is not widely available in resource-limited settings. The 107 
GeneXpert MTB/RIF sputum test (Cepheid Inc, Sunnyvale, CA), arguably the most  important 108 
commercial recent advance in the TB diagnostic field yields results within 2hours, coupled 109 
with the detection of rifampicin resistance. The Xpert test has been massively rolled out in 110 
developed countries but limitations, including relatively high operating costs and 111 
infrastructural requirements3, hamper its use in resource-constrained settings. An important 112 
limitation of diagnostic tests based on sputum, is that they are unsuitable in individuals, 113 
particularly children, who have difficulty in providing good quality sputum4, and also in 114 
individuals with extrapulmonary TB. There is an urgent need for alternative diagnostic tests 115 
that are suitable for use in all patient types, especially in resource-poor settings. Tests based on 116 
the detection of host inflammatory molecules5;6 may be beneficial, especially when applied to 117 
easily available samples such as finger-prick blood or serum.  118 
 119 
In search of immunodiagnostic tools that could be useful for the diagnosis of active TB, 120 
attempts are being made to identify novel antigens7-9. Those currently used in the Interferon-121 
gamma (IFN-γ) release assays (ESAT-6/CFP-10/TB7.7) cannot differentiate between latent 122 
and active TB. There is also a search for host markers other than IFN-γ, that are produced after 123 
overnight stimulation of blood cells with ESAT-6/CFP-10/TB7.710-14, and antibodies against 124 
novel M.tb antigens15;16. 125 
 126 
Although some T-cell-based approaches17 are promising for the diagnosis of active TB, 127 
overnight culture-based assays are not optimal as point-of-care tests. The importance of 128 
diagnosis of individuals with TB disease at the first patient contact and real-time notification 129 
to TB programs cannot be overemphasized, as delays in these steps lead to delays in the 130 
initiation of treatment and substantial loss to follow-up18. Therefore, diagnostic tests that can 131 
be easily performed at points-of-care by healthcare providers, without the need for 132 
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sophisticated laboratory equipment will contribute significantly to the management of TB 133 
disease.  134 
 135 
We conducted a study investigating the potential of protein serum host markers to identify 136 
pulmonary TB in primary health care clinic attendees from five African countries. Our aim was 137 
to further investigate the diagnostic potential of biosignatures identified in our own 138 
unpublished pilot studies in a relatively large cohort of study participants, from different 139 
regions of the African continent, as such biosignatures might be useful as point-of-care tests 140 
for TB disease.   141 
 142 
METHODS  143 
Study participants 144 
We prospectively recruited adults who presented with symptoms requiring investigation for 145 
pulmonary TB disease at primary health care clinics at five field sites in five African countries. 146 
The clinics served as field study sites for researchers at Stellenbosch University (SUN), South 147 
Africa; Makerere University (UCRC), Uganda; Medical Research Council Unit (MRC), The 148 
Gambia; Karonga Prevention Study (KPS), Malawi; and the University of Namibia (UNAM), 149 
Namibia, as part of the African European Tuberculosis Consortium (AE-TBC) for TB 150 
Diagnostic Biomarkers (www.ae-tbc.eu). Study participants were recruited between November 151 
2010 and November 2012. All study participants presented with persistent cough lasting ≥2 152 
weeks and at least one of either fever, malaise, recent weight loss, night sweats, knowledge of 153 
close contact with a TB patient, haemoptysis, chest pain or loss of appetite. Participants were 154 
eligible for the study if they were 18 years or older and willing to give written informed consent 155 
for participation in the study, including consent for HIV testing.  Patients were excluded if they 156 
were pregnant, had not been residing in the study community for more than 3 months, were 157 
severely anaemic (haemoglobin <10g/l), were on anti-TB treatment, had received anti-TB 158 
treatment in the previous 90 days or if they were on quinolone or aminoglycoside antibiotics 159 
during the past 60 days. The study protocol was approved by the Health Research Ethics 160 
Committees of the participating institutions. 161 
 162 
Sample collection and microbiological diagnostic tests 163 
Harmonized protocols were used for collection and processing of samples across all study sites. 164 
Briefly, blood samples were collected at first contact with the patient, in 4-ml plain BD 165 
vacutainer serum tubes (BD Biosciences) and transported within 3 hours at ambient 166 
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temperature to the laboratory, where tubes were centrifuged at 2500 rpm for 10 minutes, after 167 
which serum was harvested, aliquoted and frozen (–80˚C) until use. Sputum samples were 168 
collected from all participants and cultured using either the MGIT method (BD Biosciences) 169 
or Lowenstein–Jensen media, depending on facilities available at the study site. Specimens 170 
demonstrating growth of microorganisms were examined for acid-fast bacilli using the Ziehl-171 
Neelsen method followed by either Capilia TB testing (TAUNS, Numazu, Japan) or standard 172 
molecular methods, to confirm the isolation of organisms of the M.tb complex, before being 173 
designated as positive cultures.  174 
 175 
Classification of study participants and reference standard 176 
Using a combination of clinical, radiological, and laboratory findings, participants were 177 
classified as definite TB cases, probable TB cases, participants without pulmonary TB (no-178 
PTB) or questionable disease status as described in table 1. Briefly, No-PTB cases had a range 179 
of other diagnoses, including upper and lower respiratory tract infections (viral and bacterial 180 
infections, although attempts to identify organisms by bacterial or viral cultures were not 181 
made), and acute exacerbations of chronic obstructive pulmonary disease or asthma. In 182 
assessing the accuracy of host biosignatures in the diagnosis of TB disease, all the definite and 183 
probable TB cases were classified as “TB”, and then compared to the no-PTB cases, whereas 184 
questionables were excluded from the main analysis (Figure 1).   185 
 186 
Table 1: Harmonized definitions used in classifying study participants  187 
Classification Definition 
 
Definite TB 
Sputum culture positive for MTB 
OR 
2 positive smears and symptoms responding to TB treatment 
OR 
1 Positive smear plus CXR suggestive of PTB 
 
 
Probable TB 
1 positive smear and symptoms responding to TB treatment  
OR 
CXR evidence and symptoms responding to TB treatment 
 
 
 
Questionable 
Positive smear(s), but no other supporting evidence 
OR 
CXR suggestive of PTB, but no other supporting evidence. 
OR 
Treatment initiated by healthcare providers on clinical suspicion only.  
No other supporting evidence 
 
No-PTB 
Negative cultures, negative smears, negative CXR and treatment never 
initiated by healthcare providers 
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Abbreviations: CXR, chest X ray; MTB, Mycobacterium tuberculosis; TB, pulmonary 188 
tuberculosis, No-PTB, non-“pulmonary tuberculosis”. 189 
 190 
Multiplex immunoassays 191 
Using the Luminex technology, we evaluated the levels of 22 host biomarkers including 192 
interleukin-1 receptor antagonist (IL-1ra), transforming growth factor (TGF)-α, IFN-γ, IFN-γ-193 
inducible protein (IP)-10, tumour necrosis factor (TNF)-α,  IFN-α2, vascular endothelial 194 
growth factor (VEGF), matrix metallo-proteinase (MMP)-2, MMP-9, apolipoprotein A-1 195 
(ApoA-1), Apo-CIII, transthyretin, complement factor H (CFH) (Merck Millipore, Billerica, 196 
MA, USA), and C-reactive protein (CRP), serum amyloid A (SAA), serum amyloid P (SAP), 197 
fibrinogen, ferritin, tissue plasminogen activator (TPA), procalcitonin (PCT), haptoglobulin 198 
and alpha-2-macroglobulin (A2M) (Bio-Rad Laboratories, Hercules, CA, USA).  Prior to 199 
testing, samples for MMP-2 and MMP-9 were pre-diluted 1:100 following optimization 200 
experiments. Samples for all other analytes were evaluated undiluted, or diluted as 201 
recommended by the different manufacturers in the package inserts. The laboratory staff 202 
performing the experiments were blinded to the clinical groups of study participants. All assays 203 
were performed and read in a central laboratory (SUN) on the Bio-Plex platform (Bio-Rad), 204 
with the Bio-Plex Manager™ Software version 6.1 used for bead acquisition and analysis.  205 
 206 
Statistical analysis 207 
Differences in analyte concentrations between participants with TB disease and those without 208 
TB were evaluated by the Mann–Whitney U-test for non-parametric data analysis. The 209 
diagnostic accuracy of individual analytes was investigated by receiver operator characteristics 210 
(ROC) curve analysis. Optimal cut-off values and associated sensitivity and specificity were 211 
selected based on the Youden’s index19. The predictive abilities of combinations of analytes 212 
were investigated by General discriminant analysis (GDA)20 and random forests21, following 213 
the training/test set approach. Briefly, patients were randomly assigned into the training set 214 
(70% of study participants, n=491) or test set (30%, n=210), regardless of HIV infection status 215 
or study site by the software used in data analysis (Statistica, Statsoft, Ohio, USA). These 216 
training and test sets were selected using random sampling, stratified on the dependent (TB) 217 
variable. The most accurate of the top 20 marker combinations identified in the training set 218 
were then evaluated on the test sample set.  219 
 220 
RESULTS 221 
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A total of 716 individuals were prospectively evaluated in the current study. One study 222 
participant was found to be pregnant at the time of recruitment, and data for 8 other participants 223 
were not appropriately captured. These 9 individuals were excluded from further analysis 224 
(Figure 1). Table 2 shows participant characteristics.  225 
 226 
Table 2: Clinical and demographic characteristics of study participants. The number and 227 
characteristics of participants enrolled from the different study sites are shown 228 
Study site SUN MRC UCRC KPS UNAM Total 
Participants (n) 161 209 171 117 49 707 
Age, mean±SD, 
yr 
37.4±11.3 34.9±12.1 33.1±10 39.9±13.6 36.5±9.6 36.0±11.8 
Males, n(%) 68(42) 123(59) 87(51) 59(50) 28(57) 365(52) 
HIV pos, n (%) 28(17) 20(10) 28(16) 67(57) 27(55) 170(24) 
QFT pos, n(%) 105(69) 83(41) 119(70) 44(38) 35(71) 386(56) 
Definite TB, 
n(%) 
22(14) 53(25) 59(35) 18(15) 33(67) 185(26) 
Probable TB, 
n(%) 
4(2) 13(6) 4(2) 3(3) 5(10) 29(4) 
Total TB#, (n) 26 66 63 21 38 214 
No-PTB, n (%) 133(83) 140(67) 108(63) 96(82) 10(20) 487(69) 
Questionable, 
n(%) 
2(1) 3(1) 0(0) 0(0) 1(2) 6 (1) 
Table notes: SUN, Stellenbosch University, South Africa; KPS, Karonga Prevention Study, 229 
Malawi; MRC, Medical Research Council Unit, The Gambia; UCRC, Makerere University, 230 
Uganda; UNAM, University of Namibia, Namibia; SD, standard deviation; QFT, Quantiferon 231 
TB Gold In Tube; pos, positive; neg, negative; indet, indeterminate. ♯Total TB cases = all the 232 
Definite TB + Probable TB cases; TB, Pulmonary TB; No-PTB, non-“pulmonary 233 
tuberculosis”. 234 
 235 
Using pre-established and harmonized case definitions (Table 1), 185 (26.2%) of the study 236 
participants were classified as definite pulmonary TB cases, 29 (4.1%) were probable TB cases, 237 
representing the active TB group (214 participants; 30.3%), whereas 487 (68.9%) were No-238 
PTB cases and 6 (0.8%) had an uncertain diagnosis (Table 2). The characteristics of the 239 
different patient subgroups are shown in Table 3.  240 
 241 
 242 
 243 
 244 
 245 
 246 
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 247 
 248 
Table 3: Characteristics of TB and no-PTB cases and individuals with “Questionable 249 
TB” disease status.  250 
 Definite 
TB 
(n=185) 
Probable 
TB (n=29) 
ALL TB 
(n=214) 
No-PTB 
(n=487) 
Questionable 
TB  
(n=6) 
Age, mean±SD, yr 33.8±9.6 36.3±9.6 34.1±9.6 36.8±12.6 36.5±12.0 
Males, n(%) 118(64) 14(48) 132(62) 229(47) 4(67) 
HIV pos, n(%) 47 (25) 8(28) 55(26) 114(23) 1(17) 
QFT pos, n(%) 144 (78) 19(66) 164(78) 221(47) 2(33) 
QFT neg, n(%) 28 (15) 10(34) 38(18) 235(49) 3(50) 
QFT Indet, n(%) 8 (4) 0(0) 8(4) 19(4) 1(17) 
SD, standard deviation; QFT= Quantiferon TB Gold In Tube; pos, positive; neg, negative; 251 
indet, indeterminate. 252 
 253 
Utility of individual serum biomarkers in the diagnosis of TB disease  254 
All serum markers investigated showed significant differences (p<0.05) between the TB cases 255 
and No-PTB cases except A2M and MMP-2 (Supplementary Table 1), irrespective of HIV 256 
infection status. Concentrations of CFH, CRP, ferritin, fibrinogen, haptoglobulin, IFN-α2, IFN-257 
γ, IL-1ra, IP-10, MMP-9, PCT, SAA, SAP, TGF-α, TNF-α, TPA, and VEGF were significantly 258 
higher in the TB cases while those of ApoA-1, Apo-CIII, and transthyretin were higher in the 259 
no-PTB cases (Supplementary Table 1). When the accuracy for the diagnosis of TB disease 260 
was investigated by ROC curve analysis, the areas under the ROC curve (AUC) were between 261 
0.70 and 0.84 for 10 analytes: CRP, ferritin, fibrinogen, IFN-γ, IP-10, TGF-α, TPA, 262 
transthyretin, SAA and VEGF (Figure 2). Sensitivity and specificity were both >70% for six 263 
of these analytes, namely; CRP, ferritin, IFN-γ, IP-10, transthyretin and SAA (Supplementary 264 
Table 1). 265 
 266 
Supplementary Table 1: Median levels of analytes detected in serum samples from 267 
individuals with pulmonary TB disease (n=214) or no-PTB disease (n=487), and 268 
accuracies in the diagnosis of TB disease  269 
Host 
marker 
No-PTB  
(IQR) 
TB  
(IQR) 
P-value AUC Cut-off 
value 
Sensitivity 
(%) 
Specificity 
(%) 
IL-1ra 8 (0-40) 35 (0-77) <0.0001 0.63 [0.58-
0.68] 
>33.9 52.2  [45.1-
59.2] 
71.9  
[67.6-
75.9] 
TGF-α 3 (1-6) 7 (3-13) <0.0001 0.73 [69.1-
77.4] 
>5.6 62.8 [55.8-
69.4] 
76.0 [72.0-
79.8] 
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IP-10 368 (209-
652) 
1712 (808-
3558) 
<0.00001 0.82  [0.79-
0.86] 
>651.7 81.2 [75.2-
86.3] 
75.0 [71.0-
78.8] 
TNF-α 7 (3-12) 14  (8-27) <0.0001 0.69  [0.65-
0.74] 
>9.5 67.2 [60.3-
73.5] 
65.0 [60.6-
69.3] 
IFN-α2 0  (0-6) 7 (0-19) <0.0001 0.67 [0.62-
0.71] 
>2.9 59.4 [52.4-
66.2] 
71.3 [67.0-
75.3] 
IFN-γ 1 (0-3) 9 (3-21) <0.0001 0.80 [0.76-
0.84] 
>2.8 78.3 [72.0-
83.7] 
74.2 [70.0-
78.0] 
VEGF 158  (19-
286) 
341 (144-
624) 
<0.0001 0.70 [0.65-
74] 
>269.8 60.4 [53.4-
67.1] 
72.5 [68.3-
76.5] 
MMP-2 175792 
(28693-
474927) 
92881  
(22348-
312697) 
0.091 0.54 [0.49-
0.59] 
<254965 64.3 [57.3-
70.8] 
44.6 [40.1-
49.2] 
MMP-9 401540 
(155072-
756297) 
651549 
(43831-
1299700) 
0.0004 0.59 [0.53-
0.64] 
> 525174 0.56  [0.49-
0.63] 
0.62 [0.58-
0.66] 
ApoA-1 2593900 
(2101500-
3847700) 
1999800 
(1493900-
2604300) 
<0.0001 0.69 [0.65-
0.73] 
< 
2.17e+006 
0.57 [0.50-
0.64] 
0.72 [0.68-
0.76] 
Apo C-
III 
261321 
(178708-
418395) 
180967 
(115790-
297779) 
<0.0001 0.65 [0.61-
0.70] 
< 265480 0.70  [0.63 -
0.76] 
0.50 [0.45-
0.55] 
Transth
yretin 
411528 
(261059-
591773) 
184107 
(107526-
291488) 
<0.0001 0.78 [0.74-
0.82] 
< 280585 0.73  [0.66-
0.79] 
0.73 [0.68-
0.76] 
CFH 663345 
(515681-
929872) 
760622 
(599474-
1008200) 
0.0013 0.58  [0.53-
0.62] 
> 683022 0.61 [0.54 -
0.68] 
0.53 [0.49 
-0.58] 
A2M 1770000 
(712956-
3273400) 
1380700 
(501530-
3284700) 
0.141 0.54 [0.49-
0.58] 
< 
1.26e+006 
0.48 [0.41-
0.55] 
0.61 [0.57- 
0.66] 
Haptogl
obulin 
955718 
(287186-
26796000) 
2774400 
(443581-
60000000) 
0.0001 0.62 [0.57-
0.66] 
> 
6.17e+006 
0.47 [0.40-
0.54] 
0.71 [0.67 
-0.75] 
CRP 1731 (321-
9686) 
59195 
(14047-
136520) 
<0.0001 0.84 [0.81-
0.87] 
> 7251 0.82 [0.76-
0.87] 
0.73 [0.68-
0.76] 
SAP 46609 
(23028-
81115) 
63664 
(20776-
129181) 
0.0011 0.58 [0.53-
0.63] 
> 63321 0.50 [0.43-
0.57] 
0.67 [0.63-
0.71] 
PCT 4259 
(2474-
6776) 
6807 
(4399-
10000) 
<0.0001 0.68 [0.63-
0.72] 
> 5245 0.70 [0.63-
0.76] 
0.61 [0.56-
0.65] 
Ferritin 33894 
(13921-
83571) 
158610 
(61712-
365165) 
<0.0001 0.78 [0.75-
0.82] 
> 69684 0.71 [0.64-
0.77] 
0.70 [0.66- 
0.74] 
TPA 1638 (931-
2604) 
2977 
(1949-
4317) 
<0.0001 0.72 [0.68-
0.76] 
> 2163 0.70 [0.63-
0.76] 
0.66 [0.61-
0.70] 
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Fibrinog
en 
2466 
(1804-
4182) 
3987 
(2991-
6555) 
0<0.0001 0.73 [0.69-
0.77] 
> 2854 0.80 [0.74-
0.85] 
0.57 [0.53-
0.62] 
SAA 771 (279-
3985) 
6778 
(4265-
9689) 
<0.0001 0.83 [0.80-
0.86] 
> 3113 0.86 [0.80-
0.90] 
0.71 [0.67-
0.75] 
Abbreviations: CFH, complement factor H; A2M, alpha-2-macroglobulin; CRP, C-reactive 270 
protein; SAP, serum amyloid P; SAA, serum amyloid A; PCT, procalcitonin; TPA, tissue 271 
plasminogen activator; AUC, area under the ROC curve; ROC, receiver operator 272 
characteristics. Both HIV-infected and -uninfected individuals were included in the analysis. 273 
The values shown for IFN-α2, IFN-γ, IL-1ra, IP-10, TGF-α, TNF-α, VEGF, ferritin, PCT and 274 
TPA are in pg/ml. All other analyte concentrations are in ng/ml. The values in brackets under 275 
AUC, sensitivity and specificity are the 95% Confidence Intervals. 276 
 277 
 278 
Accuracy of individual host markers in HIV-uninfected study participants 279 
We stratified the study participants according to HIV infection status and repeated the ROC 280 
curve analysis. No differences were observed in the AUCs for ApoA-1, PCT and MMP-9 in 281 
HIV-positive versus HIV-negative participants. However, the AUCs for some of the acute-282 
phase proteins including A2M, CRP, ferritin, haptoglobulin, SAP and TPA, were higher in 283 
HIV-positive individuals. This was in contrast to the observations for the classical pro-284 
inflammatory host markers (IFN-γ, IP-10, TNF-α); the growth factors (TGF-α and VEGF); the 285 
blood clotting protein fibrinogen, the thyroxin and retinol transporting protein; transthyretin 286 
and CFH, which performed best in HIV-uninfected individuals (Figure 3).   287 
 288 
Utility of serum multi-analyte models in the diagnosis of TB disease  289 
General discriminant analysis (GDA) models showed optimal prediction of pulmonary TB 290 
disease with seven-marker combinations. The most accurate seven-marker biosignature for the 291 
diagnosis of TB disease, regardless of HIV infection status, was a combination of ApoA-1, 292 
CFH, CRP, IFN-γ, IP-10, SAA and transthyretin. Without any model “supervision”, this 293 
biosignature ascertained TB disease with a sensitivity of 86.7% (95% CI, 79.9-91.5%) and 294 
specificity of 85.3% (95% CI, 81.0-88.8%) in the training dataset (n=491; 168 TB and 323 no-295 
PTB), and a sensitivity of 81.3% (95% CI, 69.2-89.5%) and specificity of 79.5% (95% CI, 296 
71.8-85.5%) in the test dataset (n=210, 77 TB and 133 No-PTB). To improve test performance, 297 
we optimised the model for higher sensitivity at the expense of lower specificity, which would 298 
allow the test to be used as a screening tool. The amended cut-off values ascertained TB disease 299 
with a sensitivity of 90.7% (95% CI, 84.5-94.6%) and specificity of 74.8% (95% CI, 69.8-300 
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79.2%) in the training dataset (n=491), and sensitivity of 93.8% (95% CI: 84.0-98.0) and 301 
specificity of 73.3% (95% CI, 65.2-80.1%) in the test dataset (n=210). The positive and 302 
negative predictive values (NPV) of the biosignature were 60.6% (95% CI, 50.3-70.1 %) and 303 
96.4% (95% CI, 90.5-98.8%), respectively (Table 4). The AUC for the seven-marker 304 
biosignature (determined on the training sample set) was 0.91 (95% CI, 0.88-0.94) (Figure 4).   305 
 306 
The random forest modelling approach gave similar prediction accuracies for TB and no-PTB 307 
as GDA (87% sensitivity and 83% specificity in the training sample set, and 83% sensitivity 308 
and 89% specificity in the test sample set), without selection of any preferred cut-off values. 309 
In addition to the seven analytes included in the optimal GDA biosignature, Apo-CIII, ferritin, 310 
fibrinogen, MMP-9 and TNF-α were also identified as important contributors to top models by 311 
the random forest analysis (Figure 4).  312 
 313 
Table 4: Accuracy of the seven-marker serum protein biosignature (ApoA-1, CFH, 314 
CRP, IFN-γ, IP-10, SAA, transthyretin) in the diagnosis of TB disease regardless of HIV 315 
infection status. 316 
 317 
Training set 
(n=491) 
    
 Sensitivity Specificity PPV NPV 
%, (n/N) 
95% CI 
86.7 (130/150) 
(79.9-91.5) 
85.3 (291/341) 
(81.0-88.8) 
72.2  
(65.0-78.5) 
93.6  
(90.1-95.9) 
 
Test set (n=210) 
    
%, (n/N)  
95% CI 
81.3(52/64) 
(69.2-89.5) 
79.5(116/146) 
(71.8-85.5) 
63.4  
(52.0-73.6) 
90.6  
(83.9-94.8) 
 
Accuracy of biosignature after selection of cut-off values optimized for sensitivity 
Training set 
(n=491)  
    
 Sensitivity Specificity PPV NPV 
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%, (n/N)  
95% CI 
90.7 (136/150) 
(84.5-94.6) 
74.8 (255/341) 
(69.8-79.2) 
61.3  
(54.5-67.6) 
94.8  
(91.2-97.0) 
 
Test set (n=210)  
    
%, (n/N) 
95% CI 
93.8 (60/64) 
(84.0-98.0) 
73.3 (107/146) 
(65.2-80.1) 
60.6 
(50.3-70.1) 
96.4 
(90.5-98.8) 
 318 
Accuracy of the seven-marker biosignature in smear and culture negative patients 319 
 320 
We evaluated the accuracy of the biosignature in classifying all study participants as TB disease 321 
or “no-TB” regardless of the results of the reference standard, and particularly focused on 322 
patients who were missed by the microbiological tests (smear and culture) but diagnosed with 323 
TB disease based on clinical features including chest X-rays and response to TB treatment 324 
(Table 1). The biosignature correctly classified 74% (17/23) of patients who were smear 325 
negative but culture positive, and 67% (6/9) of patients who were both smear and culture 326 
negative. However, the biosignature only correctly classified 88% (86/98) of all the smear 327 
positive TB patients, but correctly diagnosed 91% (80/88) of these patients if the smear results 328 
were culture confirmed. 329 
 330 
Accuracy of serum biosignatures in individuals without HIV infection 331 
 332 
In the absence of HIV infection the GDA procedure indicated optimal diagnosis of TB disease 333 
when markers were used in combinations of four with ApoA-1, IFN-γ, IP-10 and SAA 334 
constituting the top model with sensitivity of 76.5% (95% CI, 67.5–83.7%) and specificity of 335 
91.1% (95% CI 86.7–94.1) in the training sample set (n=372, 115 TB and 257 no-PTB), and a 336 
sensitivity of 77.3% (95% CI, 61.8–88.0) and specificity of 87.1% (95% CI, 79.3–92.3%) in 337 
the test dataset (n=160, 44 TB and 116 no-PTB). The positive and NPV of the four-marker 338 
model in the test set were 69.4% (95% CI, 54.4–81.3%) and 91.0% (95% CI, 83.7–95.4%), 339 
respectively.  340 
 341 
 342 
DISCUSSION  343 
We investigated the potential value of 22 host serum protein biomarkers in the diagnosis of TB 344 
disease in individuals presenting with symptoms suggestive of pulmonary TB disease at 345 
peripheral-level healthcare clinics in five different African countries. Although most of the 346 
analytes showed promise individually, the most optimal discriminatory profile was a seven-347 
marker biosignature comprised of ApoA-1, CFH, CRP, IFN-γ, IP-10, SAA and transthyretin, 348 
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which might be useful in the rapid diagnosis of TB disease regardless of HIV infection status 349 
or ethnicity in Africa.  350 
 351 
Diagnostic tests based on the detection of host protein biomarkers in ex vivo samples might be 352 
more beneficial than antigen stimulation assays as results can potentially be obtained rapidly if 353 
lateral flow technologies are employed. Besides the markers that were included in our final 354 
seven-marker biosignature (ApoA-1, CFH, CRP, IFN-γ, IP-10, SAA and transthyretin), other 355 
analytes including ferritin, fibrinogen, PCT, TGF-α, TNF-α, TPA, and VEGF showed 356 
diagnostic potential for TB disease and could have equally been included in the final model in 357 
place of any of the seven selected markers. Most of these markers are well known, disease non-358 
specific markers of inflammation and have been extensively investigated in diverse disease 359 
conditions.  360 
 361 
IFN-γ, IP-10 and TNF-α, together with other markers including IL-2 (reviewed in17), are 362 
amongst the most investigated host immunological biomarkers for the diagnosis of M.tb 363 
infection and disease. Both IFN-γ and IP-10 showed potential in this study. The inclusion of 364 
these markers in the seven-marker model is not surprising, given their widely accepted roles in 365 
the pathogenesis of M.tb infection.  366 
 367 
CRP, ferritin, fibrinogen, SAA, and TPA are acute-phase proteins. The circulating levels of 368 
these proteins, as well as those of complement and clotting factors, are known to change by at 369 
least 25% in response to inflammatory stimuli, in keeping with their roles in host defense22. 370 
CRP (reviewed in22) is predominantly produced by hepatocytes. The association between 371 
serum levels of CRP, SAA and TB has long been established, including for treatment 372 
response23. Ferritin is widely known as a biomarker for iron deficiency 24, and is essential in 373 
iron homeostasis in M.tb25. Although high levels of ferritin have been observed in many non-374 
communicable diseases including cancers, disseminated M.tb disease is a common cause of 375 
hyperferritinemia26;27.  376 
 377 
PCT, the precursor molecule of calcitonin is a general inflammatory response marker that is 378 
secreted in healthy individuals by the C cells of the thyroid and by leukocytes via alternate 379 
pathways, including induction by cytokines and bacterial products after microbial infection28. 380 
Although mainly known as a diagnostic marker for bacteremia29, PCT levels have been shown 381 
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to be potentially useful in discriminating between pulmonary TB and community-acquired 382 
pneumonia in HIV-positive individuals30.  383 
 384 
ApoA-1, the major protein component of high-density lipoproteins, and CFH, a crucial 385 
regulator of the alternative complement pathway, were also amongst the markers included in 386 
our final seven-marker biosignature. ApoA-1 is one of the most important biomarkers for 387 
cardiovascular disease31, but is rarely investigated as a biomarker in TB. Like the other markers 388 
investigated in this study, ApoA-1 may not play any specific role in the pathogenesis of TB. 389 
The low levels obtained in TB patients may be a result of the many changes in lipid metabolism, 390 
which are believed to occur after the generation of the acute-phase response following an 391 
inflammatory condition31. One of the ways that CFH recognizes host cells is by binding to host 392 
markers expressed on the surfaces of cells undergoing apoptosis32. With the help of these 393 
markers, including CRP and pentraxin 3, CFH ensures proper opsonization of these cells for 394 
efficient removal without excessive complement activation during the process, thus limiting 395 
immunopathology32. This process is however believed to be exploited by M.tb, to limit 396 
opsonization and therefore avoid killing33. Like ApoA-1, lower levels of CFH were observed 397 
in the TB cases in this study.  398 
 399 
Transthyretin (reviewed in34) is a protein that is secreted by the liver into the blood and by the 400 
choroid plexus into the cerebrospinal fluid and has been widely investigated as a biomarker for 401 
nutritional status34. In previous TB studies, higher levels of transthyretin were observed in TB 402 
patients in comparison to uninfected controls35, whereas lower levels were obtained in TB 403 
patients as compared to patients with lung cancer, with serum concentrations in TB patients 404 
increasing over the course of treatment36. Our observation is in agreement with these reports.  405 
 406 
Combinations between transthyretin, CRP, SAA and neopterin ascertained TB disease with 407 
78% accuracy in a previous proteomic finger-printing study37. In our study, a biosignature 408 
containing transthyretin, CRP, SAA and markers involved in Th1-related immunity to TB 409 
(IFN-γ, IP-10), an apolipoprotein and CFH showed excellent promise as a diagnostic tool for 410 
TB. Although most of these markers are promising individually17;23;26;27;30;35-37, single host 411 
markers have many shortcomings in predicting TB disease due to  poor specificity. As observed 412 
in this large multi-centered pan-African study, the accuracy of different host markers is affected 413 
differentially by HIV infection. A biosignature containing different classes of biomarkers, 414 
produced by different cell types such as the classical Th1 immune-related markers plus acute-415 
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phase proteins, complement and apolipoproteins appears to offset the non-specific response 416 
patterns of individual or smaller groups of analytes. As a result, markers that perform relatively 417 
well in HIV-infected individuals such as the acute phase proteins, help in identifying patients 418 
who are missed by markers that may be more often affected by HIV infection such as IFN-γ 419 
and IP-10. The resultant test performance with relatively high sensitivity (93.8 %) and high 420 
NPV (96.4 %) appears promising as a screening test for active TB disease. Our data indicates 421 
that a test based on this biosignature will be superior to smear microscopy and may identify 422 
some patients who might be missed by culture. 423 
 424 
The current study stands out in that the investigations were performed in a large number of 425 
individuals recruited from peripheral level health care clinics in high-burden settings in 426 
multiple countries from different ethnic regions of the African continent. Although there is a 427 
need to evaluate the performance of the biosignature in other high TB burdened regions, the 428 
inclusion of study participants from these different ethnic regions of the African continent 429 
implies that the signature identified in this study may be highly relevant across Africa and 430 
perhaps even globally. A limitation of this study was the lack of firmly established alternate 431 
diagnoses in the no-PTB group, which is difficult in primary health care settings. This however 432 
has no bearing on the importance of our findings as the goal of any TB diagnostic test is to 433 
distinguish individuals with TB disease from those presenting with similar symptoms due to 434 
conditions other than TB. The utility of this approach in difficult-to-diagnose TB groups such 435 
as paediatric and extra-pulmonary TB has to be investigated in future studies. As the HIV 436 
infected individuals in this study were not extensively staged with CD4 counts and viral loads, 437 
it is not certain whether severe HIV infection might have any influence on the performance of 438 
the biosignature. Therefore the influence of severe HIV infection on test performance as well 439 
as the effect of anti-retroviral therapy should be investigated in future studies. Future studies 440 
should also include samples from confirmed non-TB infectious or inflammatory diseases such 441 
as non-TB pneumonia and patients with sarcoidosis and other systemic inflammatory disorders, 442 
as such patient groups will be important in ascertaining the specificity of the biosignature for 443 
TB.   444 
 445 
The biosignature identified in the current study warrants further development into a field-446 
friendly point-of-care screening test for active TB, potentially based on lateral flow 447 
technology38;39 and adapted for finger-prick blood. To allow appropriate point-of-care testing 448 
in remote settings, the final prototype would include a lightweight portable strip reader with 449 
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built-in software including an algorithm to interpret results obtained with LF strips comprising 450 
multiple cytokine test lines. Such a device is an improvement of the recently investigated UCP-451 
LF platform in a multi-site evaluation study in Africa40. A cheap point-of-care test, with a high 452 
NPV of 96.4%, would identify patients who require confirmatory testing with gold standard 453 
tests such as culture and the GeneXpert, which are technically more demanding and have to be 454 
conducted in a centralized manner. A test with performance characteristics as demonstrated 455 
here would render about 75% of the GeneXpert tests currently performed in presumed TB cases 456 
for example in South Africa unnecessary, as most of the 70 to 75% of individuals that present 457 
with symptoms, are tested, and in whom TB disease is ruled out, would be identified by the 458 
point-of-care test, thereby leading to cost savings. The GeneXpert and culture tests could then 459 
be used as confirmatory tests in individuals with positive point-of-care test results and for drug 460 
susceptibility testing.  461 
 462 
Conclusion 463 
We have identified a promising seven-marker serum host protein biosignature for the diagnosis 464 
of active pulmonary TB disease in adults regardless of HIV infection status or ethnicity. These 465 
results hold promise for further development into a field-friendly point-of-care test for TB. 466 
 467 
 468 
 469 
 470 
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FIGURE LEGENDS 634 
 635 
Figure 1: STARD diagram showing the study design and classification of study 636 
participants. CRF, case report form; TB, Pulmonary tuberculosis; No-PTB, Individuals 637 
presenting with symptoms and investigated for pulmonary TB but in whom TB disease was 638 
ruled out; ROC, Receiver operator characteristics. 639 
 640 
Figure 2: Levels of host markers detected in serum samples from pulmonary TB cases 641 
(n=214) and individuals without TB disease (n=487) and receiver operator characteristics 642 
(ROC) plots showing the accuracies of these markers in the diagnosis of pulmonary TB 643 
disease, regardless of HIV infection status. Representative plots for CRP, SAA, IP-10, 644 
ferritin, IFN-γ and transthyretin are shown. Error bars in the scatter-dot plots indicate the 645 
median and Inter-quartile ranges.  646 
 647 
Figure 3: Areas under the ROC curve for individual analytes.  AUCs obtained after data 648 
from pulmonary TB and no-PTB patients were analysed after stratification according to HIV 649 
infection status is shown as histograms (A) or ‘Before and after’ graphs (B). Host markers that 650 
performed better in HIV infected individuals are indicated by an asterix. 651 
 652 
Figure 4: Inclusion of different analytes into host biosignatures for the diagnosis of TB 653 
disease. (A) Frequency of analytes in the top 20 most accurate GDA seven-marker 654 
biosignatures for diagnosis of TB disease regardless of HIV infection status. (B) Importance 655 
of analytes in diagnostic biosignatures for pulmonary TB disease, irrespective of HIV infection 656 
as revealed by random forests analysis. (C) ROC curve showing the accuracy of the finally 657 
selected seven-marker GDA biosignature in the diagnosis of pulmonary TB disease irrespective 658 
of HIV status. (D) Frequency of analytes in the top 20 GDA biosignatures for diagnosis of TB 659 
disease in HIV-uninfected individuals. The ROC curve for TB Vs. No-PTB, regardless of HIV 660 
(C) was generated from the training dataset. 661 
 662 
